| Company Name: |
Reneo Pharmaceuticals Inc |
| Sector: |
Biotechnology |
Reneo Pharmaceuticals is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate. Co.'s primary product candidate, REN001, is a potent and selective agonist of the peroxisome proliferator-activated receptor delta. Co. is developing REN001 in rare genetic diseases that typically present with myopathy and have high unmet medical needs, including primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. The median 12 month forward target price among analysts covering RPHM is $25.0/share.
16 Cheap Stock Gambles Under $10
